PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Lauds Symrise for its Unique Eyelash Enhancing Offering - SymPeptide® 226 EL - Innovative SymPeptide® 226 EL offers superior eyelash enhancement, supporting increased bioavailability, faster results and the growth of real lashes - Awards.Frost.com
Frost & Sullivan Lauds Symrise for its Unique Eyelash Enhancing Offering - SymPeptide® 226 EL

 

NewswireToday - /newswire/ - London, United Kingdom, 2012/01/20 - Innovative SymPeptide® 226 EL offers superior eyelash enhancement, supporting increased bioavailability, faster results and the growth of real lashes - Awards.Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The 2011 Frost & Sullivan European Product Differentiation Excellence Award in the Personal Care Market is presented to Symrise for SymPeptide® 226 EL. This unique product has proven its efficacy in increasing the appearance of volume, length and thickness of eyelashes.

SymPeptide® 226 EL was developed by Symrise with the help of its partner Therapeutic Peptide Inc. (TPI) in 2009. The product offers superior eyelash enhancement, faster results and growth of real lashes. It is colorless-to-beige, odorless and easy to apply.

The use of SymPeptide® 226 EL ensures naturally beautiful and plentiful eyelashes, making the product unique in the market. Clinical studies show that it improves appearance and volume within one week.

“SymPeptide® 226 EL is a lipo-oligopeptide possessing 5 amino acids and a fatty acid. The attached lipid promotes deeper penetration into the skin and hair follicles,” notes Frost & Sullivan Vice President of Chemicals Shomik Majumdar. “Its lipophilic nature makes it highly effective, enabling it to easily reach the target site.”

The peptide in SymPeptide® 226 EL supports the production of Keratin which is the major component found in hair and eyelashes. Keratin has been found to fight signs of ageing and inflammation, while also acting as an eyelash appearance enhancer.

Most eyelash enhancers add volume to the eyelashes - temporarily. They also may have side effects including redness of the eye and skin discoloration.

“In contrast, SymPeptide® 226 EL does not cause skin irritation or discoloration,” says Dr. Sujatha Vijayan, Senior Research Analyst, Food, Drug and Cosmetics. “It truly enhances the appearance of eyelashes and not just through conventional physical thickening.”

The Product Differentiation Excellence Award is presented to the company that has demonstrated excellence in developing unique product features and functionality, in achieving superior customization and in matching target market needs. The award lauds the brand perception of the uniqueness of the product.

Frost & Sullivan Best Practices Awards recognises companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Symrise
Symrise (symrise.com) is a global supplier of fragrances, flavorings, cosmetic active ingredients and raw materials as well as functional ingredients. Its clients include manufacturers of perfumes, cosmetics and foods, the pharmaceutical industry and producers of nutritional supplements.

Its sales of €1.572 billion in 2010 place Symrise among the top four in the global flavors and fragrances market. Headquartered in Holzminden, Germany, the Company is represented in over 35 countries in Europe, Asia, the United States and Latin America.

Symrise works with its clients to develop new ideas and market-ready concepts for products that form an indispensable part of everyday life. In doing so, Symrise combines its insights into consumer trends with cutting-edge technologies, focusing on innovative trend and lifestyle products that have additional practical value for the consumer. Symrise – always inspiring more…

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Lauds Symrise for its Unique Eyelash Enhancing Offering - SymPeptide® 226 EL

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Emily Bailey 
+44(0)20 7915 7869 emily.bailey[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)